Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study

Fig. 4

Clinical response in patients treated with methotrexate (MTX) and glucarpidase. (A) Radiographic response to MTX in combination with glucarpidase, assessed using International PCNSL Collaborative Group Guidelines. Displayed is the change in target lesion diameter from baseline (%) by magnetic resonance imaging. Negative values indicate tumor shrinkage. Red indicates progression of disease (PD); orange, stable disease (SD); green, partial response (PR); purple, unconfirmed complete response (CRu); blue, complete response (CR) (B) Kaplan-Meier curves reflecting progression-free (PFS) and overall survival (OS) for study patients

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us